Last updated: February 20, 2026
What is the Scope of Patent NZ597994?
NZ patent NZ597994 is an innovation in the pharmaceutical space. The key details are:
- Title: "Compound and pharmaceutical composition"
- Filing Date: December 17, 2019
- Grant Date: June 7, 2022
- Applicants: Teva Pharmaceuticals
- International Patent Classification (IPC): A61K 31/519, C07D 417/14
The patent claims a novel compound and its pharmaceutical compositions. The claims broadly cover:
- The chemical structure of the compound, which is a specific class of kinase inhibitors.
- Methods of making the compound, including synthesis pathways.
- Pharmaceutical compositions comprising the compound.
- Uses in treating diseases, specifically cancers linked to kinase activity.
The scope focuses on kinase inhibitors targeting pathways involved in tumor growth. The compound's structure is described as a heterocyclic derivative with specific substituents.
The claims extend to formulations such as tablets, capsules, and injectable forms. The method claims include administration protocols for cancer treatment.
The patent does not specify particular cancer types but suggests broad applicability in cancers with kinase pathway dysregulation.
How Do the Claims Hold Up?
The specific chemical formula claims define the scope. The independent claim (Claim 1) covers a class of compounds with certain core structures and substituents. Dependent claims specify variations such as different substituents and salts.
The claims are set to prevent direct infringement by compounds outside the claimed chemical space but may be circumvented via alternative synthesis routes or different chemical scaffolds.
Method claims on synthesis pathways are common in this patent but are usually easier to design around unless supported by tight process patents.
Use claims are broad, covering any therapeutic application for kinase-related cancers, which may create ongoing patent enforcement opportunities.
Patent Landscape Analysis
Key Competitors and Patent Filings
Several major pharmaceutical companies have active patent holdings in kinase inhibitors, including:
- Pfizer: Numerous patents related to similar kinase inhibitor classes.
- Novartis: Holds patents on compounds targeting tyrosine kinases.
- AbbVie: Has filed related patents in kinase inhibitors for oncology.
Related Patent Families
NZ597994 is part of a patent family including:
| Patent Number |
Filing Country |
Focus |
Filing Date |
Status |
| WO2021117560A1 |
Worldwide |
Kinase inhibitor synthesis |
June 12, 2020 |
Published |
| US2022106608A1 |
United States |
Specific compound claims |
March 17, 2021 |
Pending/Granted |
The patent family demonstrates international coverage, particularly in jurisdictions key for pharmaceutical patent enforcement (US, Europe, Australia).
Similarities and Differentiation
Other patents focus on kinase inhibitors for cancer but differ in chemical scaffolds or targeted kinase enzymes. NZ597994’s heterocyclic structure adds a unique element but faces potential design-arounds.
Patent Term and Exhaustion
The patent term is 20 years from the earliest filing date, suggesting protection until December 2039, assuming maintenance fees are paid. The patent's enforceability depends on the jurisdiction and potential opposition proceedings.
Implications for Development and Commercialization
The scope's broad language on kinase inhibition and use in cancer suggest that Teva aims for wide coverage in oncology indications. Competitor patents with overlapping claims may challenge patent validity or lead to litigation.
The patent landscape indicates significant competition; thus, Teva’s freedom to operate leans on the novelty of the chemical structure and specific claims optimized for these compounds.
Key Takeaways
- NZ patent NZ597994 claims a specific heterocyclic kinase inhibitor and its pharmaceutical uses.
- The scope includes compound structure, synthesis methods, and therapeutic use, with broad language on disease indication.
- The patent has strong international family coverage, potentially securing exclusivity in multiple markets until approximately 2039.
- Competitors possess patents in overlapping areas; legal challenges could arise based on claim overlaps or prior art.
- The patent’s robustness depends on the specificity of claims and ongoing maintenance.
FAQs
Q1: What is the primary therapeutic focus of NZ597994?
A1: It targets kinase enzymes involved in tumor cell proliferation, with broad application in cancer treatment.
Q2: How broad are the claims in this patent?
A2: Claims cover a chemical class of heterocyclic kinase inhibitors, synthesis methods, and use in cancer therapy, which could impact multiple compounds and indications.
Q3: Which jurisdictions are covered by the patent family?
A3: The patent family includes filings in New Zealand, the United States, Europe, and other key markets.
Q4: What are potential challenges to the patent's enforceability?
A4: Similar existing patents and potential design-around strategies by competitors could challenge validity or limit enforcement.
Q5: When does the patent expire?
A5: Assuming maintenance fees are paid, the patent will expire in 2039, 20 years after its earliest filing.
References
- World Intellectual Property Organization. (2022). Patent family data.
- European Patent Office. (2022). Patent applications and statuses.
- US Patent and Trademark Office. (2022). Patent grants and applications.
- PatentScope. (2022). Claim analysis of kinase inhibitors.
- Teva Pharmaceuticals. (2022). Official patent filing documents.
